FIG. 2.
Surface antigen profiling of human embryonic stem cell–derived mesenchymal stem cells (hESC-MSCs) and human bone marrow stromal cells (hBMSCs) in MSC and osteogenic medium (OS). Cells were labeled and fluorescent-activated cell sorted (FACS) with: (A) antibodies against the MSC surface antigens that exhibited expression levels greater than 95%: CD29-FITC, CD44-APC, CD49e-PE, CD73-PE, CD90-PE-CY5™, CD105-PE, and CD166-PE; (B) antibodies against surface antigens that either increased or decreased markedly in osteogenic medium: CD49a-PE, STRO-1-PE, and ALP-APC; and (C) hematopoietic stem cell surface antigens: CD34 PE-CY5™ and CD45-FITC. Data from hESC-MSCs and hESC-MSCs-OS were average values from two different cell strains at passage 6 and data from hBMSC and hBMSC-OS were derived from analysis of cells from one cell strain at passage 4. The white histogram represents isotype controls and the black histogram represents the conjugated antibody of each antigen.